T1	Participants 38 75	patients with advanced gastric cancer
T2	Participants 289 363	patients with non-resectable gastric and gastro-oesophageal adenocarcinoma
T3	Participants 365 444	Three hundred and sixty-nine patients with histological proof of adenocarcinoma
T4	Participants 2124 2173	patients who had previously received chemotherapy
